Drug Profile
Research programme: anti-interleukin 12/23 monoclonal antibody - Femta
Alternative Names: FM202Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Femta Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in USA (Parenteral)